Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study.

MLA

Yolchuyeva, Sevinj, et al. “Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study.” JTO Clinical and Research Reports, vol. 4, no. 12, Nov. 2023, p. 100602. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2023.100602.

APA

Yolchuyeva, S., Giacomazzi, E., Tonneau, M., Lamaze, F., Orain, M., Coulombe, F., Malo, J., Belkaid, W., Routy, B., Joubert, P., & Manem, V. S. K. (2023). Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study. JTO Clinical and Research Reports, 4(12), 100602. https://doi.org/10.1016/j.jtocrr.2023.100602

Chicago

Yolchuyeva, Sevinj, Elena Giacomazzi, Marion Tonneau, Fabien Lamaze, Michele Orain, François Coulombe, Julie Malo, et al. 2023. “Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study.” JTO Clinical and Research Reports 4 (12): 100602. doi:10.1016/j.jtocrr.2023.100602.